Skip to main content
. 2021 Aug 20;12:699026. doi: 10.3389/fphar.2021.699026

FIGURE 2.

FIGURE 2

Reciprocal control of striatal 5-HT release by FFAR1 ligands. A FFAR1 agonist, GW9508, increased, but a FFAR1 antagonist, GW1100, decreased striatal 5-HT release without significant changes striatal DA release in FFAR1+/+ mice. However, the facilitatory effect of 5-HT release by GW9508 was completely lost in −/− mice. GW9508 (100 μM) and GW1100 (100 μM) were locally applied through a microdialysis probe as indicated by black lines. We also depicted control data from both +/+ and −/− mice by perfusing Ringer’s solution (R) during all experimental periods (A,B). The figures show mean percentage changes from baseline DA (A,C) and 5-HT (B,D) values. *p < 0.05, **p < 0.01 versus the basal values at time 0 min (Dunnett’s test). Two-way ANOVA with repeated measures indicated a significant effects of genotype [F(1, 154) = 27.1, p < 0.001], time [F(10, 154) = 2.21, p < 0.05], and genotype × time [F(10, 154) = 3.93, p < 0.01] in the facilitatory influence of GW9508 on 5-HT release (B), and a significant effects of treatment [F(1, 140) = 5.41, p < 0.05], time [F(11, 140) = 3.94, p < 0.001], and treatment × time [F(11, 140) = 2.90, p < 0.01] in the inhibitory action of GW1100 on 5-HT release (D). The post hoc tests showed that GW9508-induced enhanced 5-HT releases were significantly suppressed at 50 and 75 min time points in −/− mice, whereas GW1100 significantly reduced 5-HT release at 50 min time point in +/+ mice. ## p < 0.01, ### p < 0.001 vs. +/+ mice or vehicle control (Turky-Kramer test).